id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-010487-wncgecld	Rinella, Mary E.	STELLAR 3 and STELLAR 4: Lessons From the Fall of Icarus	2020-04-30		.txt	text/plain	1408	72	51	Here, the ASK-1 inhibitor, selonsertib, was compared to placebo in ~1700 patients with NASH and bridging fibrosis (F3, STELLAR-3) or compensated cirrhosis (F4, STELLAR-4). In the absence of a placebo controlled phase 2b study, STELLAR 3 and 4 were substantially informed by a phase 2 study, [5] in which NASH patients with F2/F3 were recruited in a multicenter trial and randomized in a 2:2:1:1:1 ratio to receive 24 weeks of treatment with 6 mg or 18 mg of selonsertib alone; 6 mg or 18 mg of selonsertib with 125 mg of simtuzumab; or 125 mg of simtuzumab alone. The STELLAR studies did not meet their primary outcomes, and selonsertib was ineffective in reversing fibrosis in NASH patients with stage F3 and F4 fibrosis -those most in need of treatment. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials	./cache/cord-010487-wncgecld.txt	./txt/cord-010487-wncgecld.txt